Track topics on Twitter Track topics that are important to you
In postmenopausal women with osteoporosis, the monoclonal antibody romosozumab was associated with a lower risk for new vertebral fractures vs. placebo at both 12 and 24 months, according to study data presented at the American Society for Bone and Mineral Research annual meeting and simultaneously published online in The New England Journal of Medicine.In a randomized, double blind, placebo-controlled, parallel-group trial, researchers found that patients assigned romosozumab (Amgen/UCB Pharma) also showed improvements in bone mass, with sustained benefits upon the transition to denosumab (Prolia, Amgen) after 12 months.NEXT ARTICLE
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...